logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jodi A. McKenzie

Eisai Inc
H指数:19
被引数:3,598

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors

一项随机研究，评估E7386联合仑伐替尼相较于医师选择治疗方案，在既往接受过铂类化疗和免疫检查点抑制剂治疗的晚期/复发性子宫内膜癌患者中的最佳剂量、有效性和安全性。

International Journal of Gynecological Cancer
IF4.7
2025-04-050
PREAI
Ramez N. Eskander; Jung-Yun Lee; Mansoor Raza Mirza; Domenica Lorusso; Helen MacKay; Isabelle Ray-Coquard; Ana Oaknin; Antonio Gonzalez-Martin; Kosei Hasegawa; Bradley R. Corr; Xiaohua Wu; Alexandra Leary; Tianle Hu; Lea Dutta; Chinyere E. Okpara; Jodi McKenzie; Vicky Makker
Characterization of tumor response with lenvatinib plus pembrolizumab (LEN plus Pembro) in the ENGOT-en9/LEAP-001 study

ENGOT-en9/LEAP-001研究中lenvatinib联合pembrolizumab（LEN plus Pembro）对肿瘤反应的表征

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Danska-Bidzinska, A.; Makker, V.; Salutari, V.; Ayhan, A.; Romero, I.; Levy, T.; McCormack, M.; Baurain, J-F.; Mach, P.; Cadoo, K. A.; Mackay, H.; Friedlander, M. L.; Santin, A. D.; Slomovitz, B. M.; Miller, D. S.; McKenzie, J.; Yao, L.; Khemka, V.; Nogueira-Rodrigues, A.; Marth, C.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

在3期CLEAR研究的最终预设生存分析中，晚期肾细胞癌患者对Lenvatinib联合Pembrolizumab的反应特征

EUROPEAN UROLOGY
IF25.2
2024-07-012
OA
Motzer, Robert J.; Choueiri, Toni K.; Hutson, Thomas; Rha, Sun Young; Puente, Javier; Lalani, Aly-Khan A.; Winquist, Eric; Eto, Masatoshi; Basappa, Naveen S.; Tannir, Nizar M.; Vaishampayan, Ulka; Bjarnason, Georg A.; Oudard, Stephane; Gruenwald, Viktor; Burgents, Joseph; Xie, Ran; McKenzie, Jodi; Powles, Thomas
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
FRONTIERS IN ONCOLOGY
IF3.3
2024-03-010
OAAI
Grunwald, Viktor; Powles, Thomas; Eto, Masatoshi; Kopyltsov, Evgeny; Rha, Sun Young; Porta, Camillo; Motzer, Robert; Hutson, Thomas E.; Mendez-Vidal, Maria Jose; Hong, Sung-Hoo; Winquist, Eric; Goh, Jeffrey C.; Maroto, Pablo; Buchler, Tomas; Takagi, Toshio; Burgents, Joseph E.; Perini, Rodolfo; He, Cixin; Okpara, Chinyere E.; McKenzie, Jodi; Choueiri, Toni K.
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer

研究309中的东亚亚组分析/主旨775: 来伐替尼联合帕博利珠单抗与医生选择化疗治疗晚期或复发性子宫内膜癌患者的比较

JOURNAL OF GYNECOLOGIC ONCOLOGY
IF3.7
2024-01-016
OAAI
Yonemori, Kan; Fujiwara, Keiichi; Hasegawa, Kosei; Yunokawa, Mayu; Ushijima, Kimio; Suzuki, Shiro; Shikama, Ayumi; Minobe, Shinichiro; Usami, Tomoka; Kim, Jae-Weon; Kim, Byoung-Gie; Wang, Peng-Hui; Chang, Ting-Chang; Yamamoto, Keiko; Han, Shirong; McKenzie, Jodi; Orlowski, Robert J.; Miura, Takuma; Makker, Vicky; Kim, Yong Man
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

晚期肾细胞癌患者的3期CLEAR研究: lenvatinib + pembrolizumab和sunitinib亚组的结果

FRONTIERS IN ONCOLOGY
IF3.3
2023-08-1620
OAAI
Grunwald, Viktor; Powles, Thomas; Eto, Masatoshi; Kopyltsov, Evgeny; Rha, Sun Young; Porta, Camillo; Motzer, Robert; Hutson, Thomas E.; Mendez-Vidal, Maria Jose; Hong, Sung-Hoo; Winquist, Eric; Goh, Jeffrey C.; Maroto, Pablo; Buchler, Tomas; Takagi, Toshio; Burgents, Joseph E.; Perini, Rodolfo; He, Cixin; Okpara, Chinyere E.; McKenzie, Jodi; Choueiri, Toni K.
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

Lenvatinib联合Pembrolizumab与舒尼替尼治疗晚期肾细胞癌的国际转移性肾细胞癌数据库联盟亚组按反应深度和疗效的生存率: 3期随机CLEAR研究分析

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2023-08-0110
OAAI
Grunwald, Viktor; Powles, Thomas; Kopyltsov, Evgeny; Kozlov, Vadim; Alonso-Gordoa, Teresa; Eto, Masatoshi; Hutson, Thomas; Motzer, Robert; Winquist, Eric; Maroto, Pablo; Keam, Bhumsuk; Procopio, Giuseppe; Wong, Shirley; Melichar, Bohuslav; Rolland, Frederic; Oya, Mototsugu; Rodriguez-Lopez, Karla; Saito, Kenichi; McKenzie, Jodi; Porta, Camillo
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

来自CLEAR试验的东亚晚期肾细胞癌患者亚组中，lenvatinib联合pembrolizumab与舒尼替尼的疗效和安全性

INTERNATIONAL JOURNAL OF CANCER
IF4.7
2023-06-093
OA
Rha, Sun Young; Choueiri, Toni K.; Matveev, Vsevolod B.; Alyasova, Anna; Hong, Sung-Hoo; Gordoa, Teresa Alonso; Gurney, Howard; Bjarnason, Georg A.; Buchler, Tomas; Pedrazzoli, Paolo; Takagi, Toshio; Park, Se Hoon; Lee, Jae Lyun; Perini, Rodolfo F.; He, Cixin S. S.; McKenzie, Jodi A.; Eto, Masatoshi
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice

Lenvatinib联合Pembrolizumab治疗或医生选择治疗的晚期子宫内膜癌患者的健康相关生活质量

EUROPEAN JOURNAL OF CANCER
IF7.1
2023-06-015
OAAI
Lorusso, Domenica; Colombo, Nicoletta; Herraez, Antonio Casado; Santin, Alessandro D.; Colomba, Emeline; Miller, David Scott; Fujiwara, Keiichi; Pignata, Sandro; Baron-Hay, Sally E.; Ray-Coquard, Isabelle Laure; Shapira-Frommer, Ronnie; Kim, Yong Man; Mccormack, Mary; Massaad, Rachid; Nguyen, Allison Martin; Zhao, Qi; Mckenzie, Jodi; Prabhu, Vimalanand S.; Makker, Vicky
Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L plus P) or treatment of physician's choice (TPC)
ANNALS OF ONCOLOGY
IF65.4
2022-06-010
OA
Lorusso, D.; Colombo, N.; Herraez, A. Casado; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; Shapira-Frommer, R.; Kim, Y. M.; McCormack, M.; Massaad, R.; Nguyen, A. Martin; Zhao, Q.; McKenzie, J.; Prabhu, V. S.; Makker, V.
THE PANORAMA OF TUMOR INTRINSIC IMMUNE REGULATORS EXHIBITED BY GENOME-WIDE CRPISR IMMUNE SCREEN INTEGRATED WITH COMPREHENSIVE CLINICAL DATASET ANALYSIS
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2021-11-100
OA
Hou, Jiakai; Wang, Yunfei; Shi, Leilei; Chen, Yuan; Xu, Chunyu; Saeedi, Arash; Pan, Ke; Bohat, Ritu; Egan, Nicholas; McKenzie, Jodi; Mbofung, Rina; Williams, Leila; Yang, Zhenhuang; Sun, Ming; Liang, Xiaofang; Ahnert, Jordi Rodon; Varadarajan, Navin; Yee, Cassian; Chen, Yiwen; Hwu, Patrick; Peng, Weiyi
A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
ANNALS OF ONCOLOGY
IF65.4
2020-11-010
OAAI
Gaspar, N.; Campbell-Hewson, Q.; Bielack, S. S.; Campbell, M.; Bautista, F.; Meazza, C.; Janeway, K.; Dela Cruz, F. S.; Whittle, S.; Morgenstern, D. A.; Dutta, L.; McKenzie, J.; O'Hara, K.; Huang, J.; Okpara, C. E.; Bidadi, B.; Koh, K-N.; Moreland, B.
A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
ANNALS OF ONCOLOGY
IF65.4
2020-09-011
OAAI
Gaspar, N.; Campbell-Hewson, Q.; Bielack, S. S.; Campbell, M.; Bautista, F.; Meazza, C.; Janeway, K.; Dela Cruz, F. S.; Whittle, S. B.; Morgenstern, D. A.; Dutta, L.; McKenzie, J.; O'Hara, K.; Huang, J.; Okpara, C. E.; Bidadi, B.; Koh, K-N.; Morland, B.
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

肿瘤糖酵解增加表征对过继性T细胞治疗的免疫抗性

CELL METABOLISM
IF30.9
2018-05-01443
OAAI
Cascone, Tina; McKenzie, Jodi A.; Mbofung, Rina M.; Punt, Simone; Wang, Zhe; Xu, Chunyu; Williams, Leila J.; Wang, Zhiqiang; Bristow, Christopher A.; Carugo, Alessandro; Peoples, Michael D.; Li, Lerong; Karpinets, Tatiana; Huang, Lu; Malu, Shruti; Creasy, Caitlin; Leahey, Sara E.; Chen, Jiong; Chen, Yuan; Pelicano, Helen; Bernatchez, Chantale; Gopal, Y. N. Vashisht; Heffernan, Timothy P.; Hu, Jianhua; Wang, Jing; Amaria, Rodabe N.; Garraway, Levi A.; Huang, Peng; Yang, Peiying; Wistuba, Ignacio I.; Woodman, Scott E.; Roszik, Jason; Davis, R. Eric; Davies, Michael A.; Heymach, John V.; Hwu, Patrick; Peng, Weiyi
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
NATURE COMMUNICATIONS
IF15.7
2017-09-06115
OAAI
Mbofung, Rina M.; McKenzie, Jodi A.; Malu, Shruti; Zhang, Min; Peng, Weiyi; Liu, Chengwen; Kuiatse, Isere; Tieu, Trang; Williams, Leila; Devi, Seram; Ashkin, Emily; Xu, Chunyu; Huang, Lu; Zhang, Minying; Talukder, Amjad H.; Tripathi, Satyendra C.; Khong, Hiep; Satani, Nikunj; Muller, Florian L.; Roszik, Jason; Heffernan, Timothy; Allison, James P.; Lizee, Gregory; Hanash, Sam M.; Proia, David; Amaria, Rodabe; Davis, R. Eric; Hwu, Patrick

研究方向

暂未获取到该数据
R
Rina M. Mbofung
H 指数:11论文数:111被引数:3,052
W
Weiyi Peng
H 指数:36论文数:346被引数:9,780
P
Patrick Hwu
H 指数:79论文数:614被引数:4.2万
L
Leila J. Williams
H 指数:16论文数:110被引数:3,147
S
Shruti Malu
H 指数:15论文数:84被引数:4,558
C
Chunyu Xu
H 指数:22论文数:58被引数:4,415
R
Rodabe N. Amaria
H 指数:45论文数:326被引数:1.6万
T
Trang N. Tieu
H 指数:13论文数:84被引数:3,066
T
Toni K. Choueiri
H 指数:149论文数:2,478被引数:12.6万
R
Robert J. Motzer
H 指数:148论文数:1,602被引数:12.3万